TY - JOUR
T1 - Factors Associated with Severe COVID-19 Among Patients with Rheumatoid Arthritis
T2 - A Large, Nationwide Electronic Health Record Cohort Study in the United States
AU - Ye, Yizhou
AU - Yue, Xiaomeng
AU - Krueger, Whitney S.
AU - Wegrzyn, Lani R.
AU - Maniccia, Anna W.
AU - Winthrop, Kevin L.
AU - Kim, Seoyoung C.
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/9
Y1 - 2023/9
N2 - Introduction: To evaluate factors associated with severe coronavirus disease 2019 (COVID-19) among patients with rheumatoid arthritis (RA) in the US. Methods: Adults with RA who had a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, based on molecular or antigen test or clinical diagnosis, were identified from the Optum® COVID-19 Electronic Health Record dataset (March 1, 2020–April 28, 2021). The primary outcome was the occurrence of severe COVID-19 (hospitalization or death) within 30 days from SARS-CoV-2 infection. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were estimated using multivariable logistic regression models to assess the association between severe COVID-19 and patient characteristics, including demographics, baseline comorbidities, and recent RA treatments. Results: During the study period, 6769 SARS-CoV-2 infections were identified in patients with RA, among whom 1460 (22%) developed severe COVID-19. Multivariable logistic regression analysis showed that being older, male, and non-White and having diabetes and cardiovascular conditions are associated with greater odds of severe COVID-19. In addition, compared with no use, the adjusted odds of severe COVID-19 were lower with recent use of tumor necrosis factor inhibitors (aOR 0.60, 95% CI 0.41–0.86) and higher with recent use of corticosteroids (aOR 1.38, 95% CI 1.13–1.69) or rituximab (aOR 2.87, 95% CI 1.60–5.14), respectively. Conclusion: Nearly one in five patients with RA developed severe COVID-19 disease within 30 days after SARS-CoV-2 infection. In patients with RA, recent use of corticosteroids and rituximab were two factors associated with a greater risk of severe COVID-19 in addition to the risk factors among demographics and comorbidities previously identified in the general population.
AB - Introduction: To evaluate factors associated with severe coronavirus disease 2019 (COVID-19) among patients with rheumatoid arthritis (RA) in the US. Methods: Adults with RA who had a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, based on molecular or antigen test or clinical diagnosis, were identified from the Optum® COVID-19 Electronic Health Record dataset (March 1, 2020–April 28, 2021). The primary outcome was the occurrence of severe COVID-19 (hospitalization or death) within 30 days from SARS-CoV-2 infection. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were estimated using multivariable logistic regression models to assess the association between severe COVID-19 and patient characteristics, including demographics, baseline comorbidities, and recent RA treatments. Results: During the study period, 6769 SARS-CoV-2 infections were identified in patients with RA, among whom 1460 (22%) developed severe COVID-19. Multivariable logistic regression analysis showed that being older, male, and non-White and having diabetes and cardiovascular conditions are associated with greater odds of severe COVID-19. In addition, compared with no use, the adjusted odds of severe COVID-19 were lower with recent use of tumor necrosis factor inhibitors (aOR 0.60, 95% CI 0.41–0.86) and higher with recent use of corticosteroids (aOR 1.38, 95% CI 1.13–1.69) or rituximab (aOR 2.87, 95% CI 1.60–5.14), respectively. Conclusion: Nearly one in five patients with RA developed severe COVID-19 disease within 30 days after SARS-CoV-2 infection. In patients with RA, recent use of corticosteroids and rituximab were two factors associated with a greater risk of severe COVID-19 in addition to the risk factors among demographics and comorbidities previously identified in the general population.
KW - COVID-19
KW - Retrospective study
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85162199106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162199106&partnerID=8YFLogxK
U2 - 10.1007/s12325-023-02533-x
DO - 10.1007/s12325-023-02533-x
M3 - Article
C2 - 37338653
AN - SCOPUS:85162199106
SN - 0741-238X
VL - 40
SP - 3723
EP - 3738
JO - Advances in Therapy
JF - Advances in Therapy
IS - 9
ER -